FY2026 EPS Estimates for HUTCHMED Increased by Trinity Delta

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) – Research analysts at Trinity Delta increased their FY2026 earnings per share (EPS) estimates for HUTCHMED in a research report issued on Tuesday, June 9th. Trinity Delta analyst L. Gregorek now expects that the company will post earnings per share of $0.30 for the year, up from their prior forecast of $0.25. The consensus estimate for HUTCHMED’s current full-year earnings is $0.47 per share.

Several other brokerages have also commented on HCM. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings lowered HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. Morgan Stanley set a $13.60 price target on HUTCHMED in a research note on Thursday, May 28th. Finally, Bank of America cut their price target on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $16.80.

HUTCHMED Stock Performance

Shares of HUTCHMED stock opened at $10.71 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96. HUTCHMED has a 12 month low of $10.40 and a 12 month high of $19.50. The stock’s fifty day moving average price is $13.20 and its 200-day moving average price is $13.95.

Hedge Funds Weigh In On HUTCHMED

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its stake in HUTCHMED by 1.2% in the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after purchasing an additional 3,801 shares during the last quarter. M&G PLC boosted its holdings in HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after acquiring an additional 54,601 shares in the last quarter. Amundi boosted its holdings in HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after acquiring an additional 8,916 shares in the last quarter. Jane Street Group LLC boosted its holdings in HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after acquiring an additional 124,771 shares in the last quarter. Finally, UBS Group AG boosted its holdings in HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares in the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.